The 'totality-of-the-evidence' biosimilarity concept requires that sufficient structural, functional, nonclinical, and clinical data are acquired in a stepwise manner, to demonstrate that no clinically meaningful differences in quality, safety, or efficacy are observed compared with the reference product. We describe the totality of the evidence for PF-06438179/GP1111 ( 
Introduction
Therapeutic antibodies currently occupy a central role in the treatment paradigm of many inflammatory diseases and cancers. [1] [2] [3] Since it was first introduced in 1998, 4 the monoclonal antibody (mAb), infliximab ([IFX] marketed as Remicade ® : Janssen Biotech, Inc., Horsham, PA, USA and Janssen Biologics B.V., Leiden, The Netherlands), 5, 6 has been widely used in the treatment of patients with immune-related diseases, including Crohn's disease (CD) and ulcerative colitis (UC). 7, 8 Just as the expiry of patent protection, data and/or market exclusivities for a small-molecule drug often opens the way for manufacturers to provide generic versions, a similar potential opportunity arises at the end of respective protection and exclusivities for biologic drugs. Since biologics are created using highly specialized and proprietary processes in living cells, it is not possible to generate an identical copy of the originator biologic or reference product (RP), and so these new versions of the originator molecules are termed biosimilars or 'similar biotherapeutic products'. 9, 10 The availability of biosimilars offers the potential for overall healthcare cost savings and increased patient access to treatments. 11, 12 The regulatory approval of biosimilars is governed by a distinct pathway, 10, 13, 14 designed to establish that the quality, safety, and efficacy of the proposed biosimilar do not result in any clinically meaningful differences compared with its RP. This regulatory approach is reflected in the 'totality-of-the-evidence' concept, 13 whereby similarity to the RP with respect to a single property or area of testing (e.g., structural, functional, nonclinical, or clinical) is not sufficient by itself to establish biosimilarity. Only by evaluation of the entire data package is it possible to conclude that a biologic product can be approved as a biosimilar. As such, establishing biosimilarity takes a stepwise approach, with considerable reliance on the comparative structural and functional characterization of the proposed biosimilar and the originator RP, in addition to conducting a nonclinical and clinical assessment (Figure 1 ). 15 The success of this approach relies on the accumulation of knowledge and understanding of the proposed biosimilar and its RP, in order to interpret any differences identified between them, and to ensure that residual uncertainties arising at any step can be addressed during the development pathway.
The European Medicines Agency (EMA) guidelines on biosimilars indicate that once biosimilarity in one indication has been demonstrated, provided there is appropriate scientific justification, extrapolation of the clinical data to other indications of the RP can be deemed acceptable. 14 In particular, consideration of extrapolation should be viewed on the basis of the totality of data obtained for the biosimilar (physicochemical and structural analyses, in vitro functional assessments, clinical efficacy, and safety and/or pharmacokinetic [PK]/pharmacodynamic [PD] data in one therapeutic indication), such that similar safety and efficacy of the biosimilar to the RP in the extrapolated indication can be expected. 16 Similarly, according to US Food and Drug Administration (FDA) guidance, 13 where there are data derived from a clinical study sufficient to demonstrate similarity in safety, purity, and potency in an appropriate condition of use, there is potential for a proposed biosimilar to be licensed for one or more additional conditions of use for which the RP is already authorized. To support extrapolation, there must be a robust scientific justification that addresses issues related to the indication in which the proposed biosimilar was assessed, and to the extrapolated indications. Scientific justification must include consideration of: the mechanism of action (MOA) in each indication for which authorization is sought; the PK and biodistribution of the proposed biosimilar across different patient populations (relevant measures of PD effect may yield valuable evidence to validate the MOA); differences in toxicity that can be anticipated in each indication and patient population; and any other factor that may affect the safety or efficacy of the proposed biosimilar in each condition and patient population for which licensure is sought. 20 Binding of the Fab domain of IFX to sTNF results in disruption of TNF ligand-receptor signaling and inhibition of an inflammatory cascade, leading to downregulation of adhesion molecule expression, induction of apoptosis, activation, and secretion of other pro-inflammatory cytokines, and a reduction of the inflammatory infiltrate. 22 IFX binding to mTNF may also result in Fc domain-mediated mechanisms for neutralizing pro-inflammatory effects. 20 Binding and neutralization of TNF is common to anti-TNF mAbs, and this MOA is applicable across all disease indications of IFX (Table 1) . 8, 20, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] However, binding of sTNF does not completely account for the effectiveness in IFX in the treatment of CD, and binding to mTNF appears to be of additional importance in this indication. 23, 24 The IFX/mTNF complex on the TNF-producing cell can block the binding to TNFR1/R2 on TNF-responsive cells, thereby inhibiting TNFinduced apoptosis. In a TNF-producing cell, binding of the Fab domain of IFX to mTNF can also result in 'reverse signaling' and a response such as cell apoptosis.
Where IFX has bound to mTNF, it is also possible that a cytotoxic effect is produced via the Fc domain through either antibody-dependent cellmediated cytotoxicity (ADCC) or complementdependent cytotoxicity (CDC 39, 40 FcγRIIIa polymorphisms have been reported not to be clinically significant to IFX treatment. 41, 42 While the prominence or the contributions of the MOAs of IFX outlined above may differ across disease indications, there is a consistent role for neutralization of the TNF-mediated inflammatory response via disruption of ligand-receptor interaction and function by IFX across a range of chronic, inflammatory disorders (Table 1) . 
Totality-of-the-evidence approach to establishing the biosimilarity of PF-SZ-IFX to ref-IFX

Structural and functional assessment Multiple lots of ref-IFX-US and ref-IFX-EU pur-
chased over several years were analyzed alongside PF-SZ-IFX drug substance and drug product in the similarity exercise, which is described in detail elsewhere 43 43 Extensive characterization, using MS techniques and enzymatic treatment, concluded this was due to the different level of heavy-chain C-terminal Lys present in each product. 43 C-terminal Lys is a commonly observed structural feature in the basic species of mAbs and is rapidly cleaved in vivo. 48 The different levels observed can be attributed to the cell lines used in the manufacture of the respective products. The structural differences in N-linked glycans and C-terminal Lys between products outlined above were not expected to impact efficacy or safety. 49 The extensive in vitro functional similarity assessment performed included biological assays reflecting the key attributes underlying the mechanisms of action of IFX across disease indications. between products was also determined in terms of their Fc domain activity, since functional assays assessing ADCC and CDC showed comparable dose-response curves and relative potencies between products. 42, 43 These findings were ultimately substantiated by the similarity in efficacy and safety between PF-SZ-IFX and ref-IFX-EU in the comparative clinical study in patients with RA, 50 confirming that the structural differences described above were not clinically relevant and did not prevent a conclusion of biosimilarity of PF-SZ-IFX to ref-IFX.
Despite mAbs being highly complex, the analytical and in vitro biological assays used to characterize them are sufficiently sensitive to distinguish even minor variations between the originator RP and a proposed biosimilar. The need to establish whether any structural or functional differences observed as part of the analytical assessment have a clinical impact highlights the importance of the totality-of-the-evidence approach towards establishing biosimilarity. 51 This comparative study was conducted in rats because of ethical concerns associated with the use of chimpanzees (the only pharmacologically relevant species for toxicity testing with IFX), and the lack of toxicity observed in studies conducted with ref-IFX in rats, chimpanzees, mice, or rabbits. 51 In this single-dose toxicokinetics/tolerability study in rats, the effects of PF-SZ-IFX (10 mg/kg or 50 mg/kg) on mortality, clinical signs, body weight, anti-drug antibody (ADA) response, and exposure were similar to that of ref-IFX-EU. 43 These results demonstrated similarity of PF-SZ-IFX to ref-IFX-EU for nontarget mediated effects on tolerability, ADA response, and overall exposure. In addition to the findings from the structural and functional assessments, the results of this nonclinical toxicokinetics/tolerability study in male rats provided additional support for the totality of the evidence demonstrating biosimilarity of PF-SZ-IFX to ref-IFX.
Nonclinical assessment
Clinical similarity assessment
Clinical studies were performed to provide confirmatory evidence for the biosimilarity of PF-SZ-
IFX and ref-IFX-US/ref-IFX-EU established
from the structural and functional assessments and based on the results of the nonclinical in vivo study. The clinical development program that confirmed the similarity of PF-SZ-IFX to ref-IFX comprised a phase I PK similarity study in healthy subjects, 52 and a comparative efficacy and safety study in patients with moderately to severely active RA (Figure 3 ). 50 Pharmacokinetics. In PK studies conducted in various patient populations, it was previously shown that following single or repeated intravenous administration of ref-IFX at doses of 3-20 mg/ kg, there was a linear relationship between the dose administered and the maximum serum concentration (C max ) and area under concentration-time curve (AUC) values. 5, 53 The median terminal halflife ranged from 7.7 to 9.5 days, after single doses at 3-10 mg/kg in patients with RA, 5 mg/kg in patients with CD, and 3-5 mg/kg in patients with plaque psoriasis. The formation of ADAs is known to affect the PK of IFX in patients with RA. 54 Higher serum IFX concentrations at a low IFX dose (1 mg/kg) in patients with RA receiving repeated IFX dosing with concomitant administration of methotrexate (MTX) can be ascribed to suppression of ADA formation, and the IFX concentration being unaffected. 55 While the PK of IFX is similar across the approved indications, the extent of ADA formation, the use of-and response to-concomitant immunosuppressants, and their impact on PK parameters may differ. 31, 32, [55] [56] [57] [58] Nevertheless, it was anticipated that the PK profile for PF-SZ-IFX and ref-IFX should be similar, regardless of the patient setting, because of the similarity in structural and functional in vitro data that had already been established. Clinical efficacy. An RA patient population was selected for the comparative efficacy and safety trial (Study B5371002) since it provides a sensitive setting to detect differences among effective treatments, and it has a large clinical utilization, immunogenicity, and safety experience amongst the various IFX-licensed indications. 59 The efficacy and safety of PF-SZ-IFX and ref-IFX-EU were compared in RA patients with an inadequate response to MTX. 50 In both the intent-totreat and per-protocol populations, the two-sided 95% CIs and 90% CIs of the treatment difference in the 20% improvement in American College of Rheumatology (ACR) criteria (ACR20) Clinical safety. The safety population in Study B5371001 comprised 146 subjects: 49 subjects randomized to the PF-SZ-IFX arm, 48 subjects randomized to the ref-IFX-US arm, and 49 subjects randomized to the ref-IFX-EU arm. 52 All treatments were found to be generally safe and well tolerated. Clinical immunogenicity. The occurrence of immunogenicity to biologics is complex and influenced by various intrinsic and extrinsic factors. 60 The factors influencing the development of ADAs can be related to treatment (e.g., dose and duration, frequency, route of administration); product (e.g., amino acid sequence or glycosylation pattern); process (e.g., manufacturing, storage, handling, impurity profile); and patient population (e.g., genetic predisposition, immunosuppressed). Incidence of ADAs can also vary between studies due to the format, sensitivity, and specificity of the assay, as well as aspects such as the threshold used or the sampling schedule. 61 While it is known that the immunogenicity of ref-IFX is not the same across all patient populations within its licensed indications, 6 it was anticipated that the immunogenicity profiles for PF-SZ-IFX and ref-IFX should be similar, irrespective of the patient setting, since the intrinsic and extrinsic factors would be the same.
All three treatment groups (PF-SZ-IFX, ref-IFX-EU, and ref-IFX-US) in Study B5371001 had an overall comparable incidence of ADA. 52 In Study B5371002, conducted in patients with RA, the overall proportions of ADA-positive patients to week 30 for the PF-SZ-IFX (48.6%) and ref-IFX-EU (51.2%) arms were similar. 50 Approximately 80% of all ADA-positive patients overall also tested positive for neutralizing antibody (NAb); the ADA/NAb results were balanced between treatment arms. 50 Overall, immunogenicity assessments were consistent with the findings from the analytical structural and functional, and nonclinical, assessments in that there were no meaningful differences between PF-SZ-IFX and ref-IFX-EU or ref-IFX-US. Moreover, these findings confirmed that the immunogenicity profile of PF-SZ-IFX was unaffected by being manufactured in a different cell line to that used to produce ref-IFX. 
Extrapolation of indications
Conclusion
The totality-of-the-evidence approach for PF-SZ-IFX was built on regulatory and scientific principles. Extensive studies to determine the structural and functional characteristics of PF-SZ-IFX provided the foundation for the similarity assessment. 42 
